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Lipids account for the majority of pulmonary surfactant, which is essential for normal breath-
ing. We asked if interstitial lung diseases (ILD) in children may disrupt alveolar surfactant
and give clues for disease categorization.
Methods
Comprehensive lipidomics profiles of broncho-alveolar lavage fluid were generated in 115
children by electrospray ionization tandemmass spectrometry (ESI-MS/MS). Two refer-
ence populations were compared to a broad range of children with ILD.
Results
Class and species composition in healthy children did not differ from that in children with
ILD related to diffuse developmental disorders, chronic tachypnoe of infancy, ILD related to
lung vessels and the heart, and ILD related to reactive lymphoid lesions. As groups, ILDs re-
lated to the alveolar surfactant region, ILD related to unclear respiratory distress syndrome
in the mature neonate, or in part ILD related to growth abnormalities reflecting deficient
alveolarisation, had significant alterations of some surfactant specific phospholipids. Addi-
tionally, lipids derived from inflammatory processes were identified and differentiated. In
children with ABCA3-deficiency from two ILD causing mutations saturated and monounsat-
urated phosphatidylcholine species with 30 and 32 carbons and almost all phosphatidylgly-
cerol species were severely reduced. In other alveolar disorders lipidomic profiles may be
of less diagnostic value, but nevertheless may substantiate lack of significant involvement
of mechanisms related to surfactant lipid metabolism.
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Conclusions
Lipidomic profiling may identify specific forms of ILD in children with surfactant alterations
and characterized the molecular species pattern likely to be transported by ABCA3 in vivo.
Background
In the lungs, the alveolar space forms a vital and metabolically highly active compartment re-
sponsible for gas-exchange and host defense [1]. A thin layer of a surface-active material called
surfactant covers the epithelium towards the air spaces, where its role is to lower the surface
tension and prevent end-expiratory collapse of the alveoli. Pulmonary surfactant is a complex
mixture of lipids (about 80–90%) and surfactant specific proteins [2]. The composition and
function can variably be affected by many respiratory diseases [3]. A precise characterization of
the lipids of this compartment, which are accessible by broncho-alveolar lavages, may yield
clues for the diagnostic categorizing of pulmonary diseases affecting the alveolar space, for in-
sights into the metabolism of its numerous components, and for therapeutic interventions to
correct disease induced alterations.
Up to now neither in healthy children nor in the large group of human diseases affecting the
alveolar surfactant compartment, comprehensive lipidomic analysis with state of the art tech-
nology has been performed. Lipids and phospholipid classes have been investigated in a num-
ber of studies in healthy subjects und many lung diseases [3]. Analysis of the species
composition of these lipids has been achieved for a very limited number of conditions and
phospholipid classes. These include phosphatidylcholine species in the bronchoalveolar lavage
fluid from control children and children with acute lung injury [4], children with asthma [5],
infection and cystic fibrosis [6,7], premature infants with respiratory distress syndrome who
went on to develop chronic lung disease [8–10] and in adults with Pneumocystis pneumonia
and acquired immunodeficiency syndrome [11]. Species composition of phosphatiylglycerol
and phosphatidylinositol were reported in some of the diseases. Most closely extensive lipido-
mics of cellular and secreted phospholipids has been analyzed in isolated and differentiated
human fetal type II alveolar epithelial cells [12].
Chronic childhood interstitial lung diseases (chILD) represent a large spectrum of mostly
rare diffuse parenchymatous diseases, prevalent in children of all ages [13,14]. Many of these
diseases directly affect varying components the pulmonary surfactant system, including geneti-
cally caused deficiency of the lipid transporter ABCA3 [15], surfactant protein (SP) SP-C and
SP-B deficiency [16], and deficiency of the transcription factor TTF1 [17,18]. There exist many
more diseases with the typical clinical presentation of chILD, however without characterization
as yet. In addition, all the other forms of ILD might have an impact on the pulmonary surfac-
tant lipid system. We hypothesized that several of these conditions are affected and that lipido-
mic analysis may help to identify such entities. By this candidates might be identified for
genetic abnormalities leading to disturbances of the pulmonary surfactant system. In addition
we expect that grouping of diseases into clinical subcategories might also generate relatively ho-
mogenous and distinct lipid profiles which may significantly differ between groups, supporting
the value of the classification system.
To address these hypothesis experimentally, a cohort of more than 100 children suffering
from diffuse parenchymatous diseases, which had been diagnosed clinically to varying extent
at the discretion of the attending physician and for the most part according to the principles of
the recent ATS state of the art proposal [19], was grouped into an extended classification
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system, based on the one originally proposed by Deutsch et al and Langston et al. [13,20].
Comprehensive lipidomic analysis of their lavage lipids, including the alveolar surfactant sys-
tem was performed and compared to that of a healthy control group. In addition a second
non-chILD comparison group, i.e. children with bronchitis, was used.
Methods
Patient selection
Between 1997 to 2007 all cases sent to our lab for biochemical and surfactant analysis were
carefully diagnosed to have diffuse parenchymal lung disease, i.e. interstitial lung disease, by
history, findings, course and sometimes histological and genetic means, as part of the routine
work up of these patients. Of these, 111 had chronic (> 4 weeks) diffuse parenchymal lung dis-
ease affecting both sides of the lungs by radiology, gave informed consent and had lavage mate-
rial available for analysis. The children were further categorized diagnostically into one of the
ILD categories listed in Table 1 and a definite clinical diagnosis was obtained at the highest
level possible in each case. These patients were compared to 16 healthy controls (controls-
healthy) and 16 disease controls, i.e. children assessed for chronic cough and exclusion of cystic
fibrosis, structural abnormalities, immune deficiencies, allergic airway disease and primary cili-
ary dyskinesia (controls-bronchitis). The individual diagnoses and lipidomic results are listed
in S1 Table. Patients 264, 644, 1180 [21], 641 [22], 90 [23], 497 [24] were included in the previ-
ous manuscripts indicated. More details are indicated in S1 Methods.
Broncho-alveolar lavages, sample preparation and biochemical analysis
Broncho-alveolar lavage supernatant was extracted in the presence of not naturally occurring
lipid species as internal standards and crude lipid extracts were quantified by direct flow injec-
tion electrospray ionization tandem mass spectrometry (ESI-MS/MS) in positive ion mode
[25,26] and more detailed in the supplement. Lipid species were annotated according to the re-
cently published proposal for shorthand notation of lipid structures [27].
Calculation and expression of lipid results
Results are presented as total lipids, total phospholipids, cholesteryl ester and free cholesterol
(all expressed as nmol/ml) (Fig. 1, panel A in S1 Fig.). Species were only taken into consider-
ation for presentation if the species had an abundance of 0.5%. To guarantee quality of anal-
ysis and to eliminate a sample factor, diluted bronchoalveolar lavages with a total lipid
concentration< 15 μmol/l or a phospholipid concentration< 10 μmol/l were excluded from
calculations, as most lipid species are below or close to the limit of detection. In total 28 of the
143 subjects were excluded from the final analysis, as detailed in Table 1.
Ethics Statement
The study was approved by the institutional review board, the Ethikkommission der Med.
Fakultät der LMUMünchen, Pettenkoferstr. 8, 80336 München (EK 026–06) and all parents or
guardians gave their written informed consent, and the children gave assent. Samples from the
controls-healthy were collected during a previous study [28].
Statistical analysis
For quality control and multivariate, unsupervised data analysis we performed a principle com-
ponent analysis (PCA) using the NIPALS method from the pcaMethod package in the R 3.1.1
statistical software (http://www.r-project.org) [29]. The analysis was based on the
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1 Controls—healthy Healthy n. a. 7.1 16 5 11
2 Controls—
Bronchitis
Normal alveolar cell count and
differential in BAL




Alveolar capillary dysplasia with
misalignment pulmonary veins





Intrauterine growth retardation (due to
alcohol)(1), Pulmonary hypoplasia
(5), Related to chromosomal
disorders (4), Related to preterm birth
(BPD-cLDI, Mikity-Wilson-Syndrome)
(13)
0.1 2.2 23 5 18
5 Immuno-intact host Eosinophilic alveolitis (2), Exogen
allergic alveo1itis/Hypersensitivity
pneumonitis (5)




Phagocyte defects (1), T-cell
deficiency (2), Miscellaneous (4)
3.5 5.8 9 1 8
7 Chronic tachypnoe
of infancy
No further differentiation 0.4 3.6 10 1 9
8 Reactive lymphoid
lesions
Nodular lymphoid hyperplasia of the
lung (2), Follicular bronchitis/
bronchiolitis (1), Lymphocytic
interstitial pneumonia (LIP)(1)
3.3 8.9 4 4
9 Related to alveolar
surfactant region
ABCA 3 (1 mutation)(5), ABCA 3 (2




pneumonia (2), Nkx 21 gene defect
(1), Nonspecific interstitial pneumonia
(NSIP)(1), NSIP + pulmonary alveolar
proteinosis (PAP) +
Microvasculopathy (1), Surfactant
protein B mutation (3), Surfactant
protein C mutation (3)
1.0 5.5 24 3 21
10 Related to lung
vessels /heart
Congestive changes related to
cardiac dysfunction (2), Lymphatic
disorders (1), M. Osler (1), Pulmonary
capillary hemangiomatosis (1),
Pulmonary hypertension (2)
2.8 7.8 7 7
11 Related to systemic
diseases
Alagille-Syndrome (arterohepatic
dysplasia) (1), Familial dysautonomia





vascular disorders (4), Sarcoidosis
(1)
5.5 9.1 10 3 7
12 Unclear RDS in the
mature neonate
No/low SP-C biochemically (3), No/
low SP-B biochemically (4), Familial
(1), Pulmonary hypertension (2), No
further classification (5)
0.0 1.0 15 2 13
All 143 28 115
doi:10.1371/journal.pone.0117985.t001
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concentration on log scale of 143 lipid subspecies for 115 patients. No significant batch effects
were identified (panel B in S1 Fig.), additionally this was confirmed by calculating PCA using
absolute and relative lipid data (not shown). Group comparisons were primarily made between
healthy controls and the other groups (A) and B) in panel A in S1 Fig.). As the data were mostly
but not always normally distributed non-parametric Kruskal-Wallis ANOVA and Dunn’s post
hoc tests were used; groups with 3 or less subjects were excluded from the analysis (Prism 4
software (San Diego, CA, U.S.A). We accounted for multiple testing by false discovery rate
(FDR) correction for p-values from 153 ANOVA tests (for lipid classes and species). For FDR
correction at a global significance level of 0.05, the new significance cut-off was 0.0182. Data in
the tables are expressed as means and standard deviations, in the supplemental material addi-
tional descriptors are given in tables in S3 Table.
Lastly, the results were displayed on the level of molecularly or clinically defined diseases
(C) in panel A in S1 Fig.). Here no statistical comparisons were made except for phosphatidyl-
choline and phosphatidylglycerol in patients with two ABCA3 mutations (S2 Table). FDR was
used for correction of the multiple lipid classes and species compared.
Fig 1. Calculation and expression of the results of the lipid analysis. All analyzed lipids are the sum of all analyzed phospholipid classes, cholesteryl
ester and free cholesterol (all expressed as nmol/ml). Phospholipid classes are expressed as % of all analyzed phospholipids and the species as percentage
of that phospholipid class. In the body of the manuscript mainly the results of all lipid classes and the composition of one of its classes, i.e.
phosphatidylcholine, are indicated. Composition of the other classes are presented in the supplemental materials. For overview see also panel A in S1 Fig.
doi:10.1371/journal.pone.0117985.g001
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Results
A) Lavage lipidomics in healthy children
For the first time extensive BAL lipidomics profile of children with a normal alveolar surfac-
tant, i.e. healthy children and those with bronchitis and as such with no or very little impact
on the alveolar space were determined comprehensively. We analyzed lavage for many of its
lipids (Fig. 1) and found that total phospholipids constituted more than 85%; free cholesterol
was about 10% and a small amount were cholesteryl esters (Table 2). Among the phospholipid
species, phosphatidylcholine was by far the most abundant, as expected for pulmonary surfac-
tant (Fig. 2A), with dipalmitoyl-phosphatiylcholine (32:0) as the main species (Fig. 2B).
When compared to the healthy children, the children with bronchitis had a similar pattern
with no differences in classes; however there were some difference in minor species of the
non-surfactant lipid classes phosphatidylethanolamine, phosphatidylserine, plasmalogens
and cholesteryl esters. This underscores the susceptibility of lipid species composition to in-
fluences from bronchial inflammatory processes (S2 Fig.), even if only few and not all cell
lipids typical for cells are altered. To readily detect the extent, single values are displayed
(Fig. 3, S3 Fig.).
B) Covering the whole clinical spectrum of childhood interstitial lung
disease
In our large disease cohort we present lavage lipidomics data of all disease categories created so
far in the currently used classification system of chILD [13,30]; these include in particular dis-
ease groups predominantly prevalent in infancy, like diffuse development disorders, growth ab-
normalities reflecting deficient alveolarisation, chronic tachypnoe of infancy, and disorders
related to alveolar surfactant region. We introduced the category “children with unclear RDS
(respiratory distress syndrome) in the mature neonate” for cases where no histologic or genetic
investigations were done (Table 1, S1 Table for individual values and outcomes). By this we
were able to include these patients for lipidomic analysis and we could test the hypothesis if
their lipid profile would give a clue to their disease category.
Total lipids, total phospholipids, free cholesterol and cholesteryl esters classes were not
statistically different between different disease categories (Table 2).
Differences of phospholipid classes were only identified in ILDs related to the alveolar sur-
factant region and ILD related to unclear RDS in the mature neonate. Phosphatidylcholine, the
major surfactant phospholipid, was low in ILDs related to the alveolar surfactant region, and
phosphatidylglycerol, the other major surfactant phospholipid was low in this disease group
and in unclear RDS in the mature neonate (Table 3, second column; Fig. 3 and S3 Fig.).
On the species level, in ILD related to alveolar surfactant region, dipalmitoyl-phosphati-
dylcholine (PC 32:0), the most abundant phosphatidylcholine species, was low. Characteristic
changes were demonstrated for phosphatidylglycerol species 35:1 and 36:1, which were low in
addition to the aforementioned disease groups, in ILD related to Growth abnormalities re-
flecting deficient alveolarisation. A separation mainly of ILD related to the alveolar surfactant
region, but also cases of ILD related to unclear RDS in the mature neonate and ILD related to
Growth abnormalities reflecting deficient alveolarisation from the other samples was ob-
served during unsupervised data analysis using principal component analysis (panel B in
S1 Fig.).
In these three disease groups with deviations of surfactant characteristic lipids, specific alter-
ations of species with long fatty acid chains of sphingomyeline, phosphatidylethanolamine,
plasmalogens, phosphatidylserine and cholesteryl esters were noted to various degrees, as were
Surfactant Lipidomics in Children
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mainly increases of ether phosphatidylcholines, abundant in white blood cells. Such changes
were also observed in ILD related to systemic diseases.
Apart from only very mild degree as in Controls-Bronchitis, changes of the plasmalogens
were identified in ILD in the Immuno-intact or Immuno-compromised host (Table 3, S3 Fig.)
no changes of the lipid profile were demonstrated in the four ILD groups: ILD related to
Fig 2. A) Phospholipid classes of the control groups (healthy (n = 11), left column of pair; bronchitis (n = 10), right column of pair). Lipid class
composition is expressed as % of the analyzed displayed lipid classes (left graph). B) Phosphatidylcholine species composition is expressed as %
phosphatidylcholine (right graph). The species of the other phospholipid classes are displayed in the S2 Fig. Data are means. Species present at an
abundance of< 0.5% were not displayed.
doi:10.1371/journal.pone.0117985.g002
Fig 3. Display of results at the disease category level. A) Phosphatidylcholine, the major surfactant phospholipid class and B) its species
dipalmitoylphosphatidylcholine (PC 32:0) are given as individual results of all patients included in the study according the disease category they belong to.
The statistical comparisons were done by ANOVA and Dunn’s post hoc test; all significant results are displayed in each figure. To take multiple comparisons
into consideration, an overall cut-off level of P<0.0182 was calculated. For A) 1-way ANOVA gave a P = 0.0020, for B) P< 0.0038; the significant results of
Dunn’s post hoc tests are indicated as following: ____ = P< 0.05, _ _ _ = P< 0.01, and . . .. = P< 0.001. The species of the other phosphatidylcholines, the
other phospholipid classes and their species composition are displayed in S3 Fig. Horizontal bar indicates median.
doi:10.1371/journal.pone.0117985.g003
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Chronic tachypnoe of infancy, ILD related to reactive lymphoid lesions, ILD related to lung
vessels/heart and ILD related to diffuse developmental disorders.
Taken together these findings demonstrate that on the level of ILD-disease categories alter-
ations of the lipid profile related to pulmonary surfactant are present only in few disease cate-
gories, which are also associated with changes in non-surfactant lipids.
Fig 4. Display of results at the individual diagnosis level for the disease category “ILD-related to the alveolar surfactant region”. Lipid class
composition (graph A) on left side) and phosphatidylcholine species composition (graph B) on right side) are indicated as means for each diagnosis. The
number of subjects is detailed in Table 1. The numbers above the columns indicate the mean phospholipid concentrations (μmol/l). No statistical
comparisons were done; the graphical display should allow a rapid identification of deviations from the controls. The other species are provided in S4 Fig.
Only lipid species present at an abundance of> 0.5% are displayed.
doi:10.1371/journal.pone.0117985.g004
Fig 5. Display of results at the individual diagnosis level for the disease category “ILD related to unclear RDS in the mature neonate”. Lipid class
composition (graph A) on left side) and phosphatidylcholine species composition (graph B) on right side) are indicated as means for each diagnosis. The
number of subjects is detailed in Table 1. The numbers above the columns indicate the mean phospholipid concentrations (μmol/l). No statistical
comparisons were done; the graphical display should allow a rapid identification of deviations from the controls. The other species are provided in S5 Fig.
Only lipid species present at an abundance of> 0.5% are displayed.
doi:10.1371/journal.pone.0117985.g005
Surfactant Lipidomics in Children
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C) Lavage lipidomics of molecularly and clinically defined diseases
We next resolved the level of the disease categories now considering the molecularly or clinical-
ly defined diseases (Table 1, S1 Table). As visual inspection of the data shows, in many of the
diseases no differences of the phospholipid classes as well as their species composition were
identified in comparison to the controls. Such diseases included all those within the categories
Diffuse developmental disorders, Immuno-intact host, Immuno-compromised host, Chronic
tachypnoe of infancy, Reactive lymphoid lesions, Related to lung vessels/heart and Related to
systemic diseases (Table 3, S3 Fig.). We took a closer look at the two categories with diseases
likely involving the pulmonary surfactant system. These were Figure SILDs related to the alveo-
lar surfactant region (Fig. 4, S4 Fig.), and ILDs due to unclear RDS in the mature neonate
(Fig. 5, S5 Fig.). Due to the low number of cases in many specific diseases statistical analysis
was omitted; lipid composition of the latter should be appreciated on an individual basis (S1
Table), except for the group of children with two ABCA3 mutations.
ABCA3-mutations. Patients with ABCA3-deficiency from two disease causing mutations
had their level of phosphatidylcholine reduced by 50% with pronounced changes of its species
profiles, i.e. PC 32:0 lower and increased PC 38:5 (S2 Table). Phosphatidylglycerols PG 32:1,
PG 36:1, PG 36:4, PG 38:4 and PG 38:5 were all decreased (S2 Table, Fig. 5, S5 Fig.).
We hypothesized that the molecular species composition of broncho-alveolar lavage could
give us a clue to the specificity of the failing transporting activity of ABCA3. Thus we
Fig 6. Display of results at the individual diagnosis level “ABCA3 transporter deficiency, twomutations/Controls-healthy” (panel A) and B)) and
“Controls-bronchitis/Controls-healthy” (panel C) and panel D)). A) and C) Phosphatidylcholine and B) and D) Phosphatidylglycerol species of the
children with ABCA3 transporter deficiency due to two disease causing mutations (n = 5) or controls-bronchitis (n = 10) in relation to that of the control
children (n = 11). Mean values of each group were taken for calculation of the ratio. A ratio below 1 indicates lower values in the children with ABCA3
transporter deficiency, i.e. lack of transport of such species into the alveolar space; a ratio above 1 indicates higher values in the children with ABCA3
transporter deficiency, i.e. accumulation of such species in the alveolar space.
doi:10.1371/journal.pone.0117985.g006
Surfactant Lipidomics in Children
PLOS ONE | DOI:10.1371/journal.pone.0117985 February 18, 2015 11 / 18
normalized lipid species to those found in the control-healthy group and compared to those in
the control-bronchitis patients with the same ratio (Fig. 6). Phosphatidylcholine species with
the shorter fatty acid chains and none or one double bond (PC 30: to 32:1) including dipalmi-
toyl-PC (PC 32:0) had ratios significantly (P< 0.01) below 1, indicating reduced delivery to
the alveolar compartment. For phosphatidylglycerol the same observation was made for species
PG 32:1, PG 34:0 and those with longer fatty acid chains (PG 36 to 38, except PG 36:3), irre-
spective of their degree of saturation.
Discussion
Here we present a comprehensive lipidomics profiling of the broncho-alveolar lipids, including
surfactant lipids of healthy children. In addition to composition reported for phosphatidylcho-
line and phosphatidylglycerol [6,31], we inform detailed on the species composition of normal
surfactant, except for phosphatidylinositol, which we did not assess. We introduced a second
comparison group, controls-bronchitis. From these children with limited bronchial inflamma-
tion in the absence of alveolar disease, surfactant material was recovered which had almost the
same composition. The large number of lipids assessed differed merely in few species, most of
these lipids typically found in cellular membranes or plasma compartments, including
phosphatidylethanolamine, phosphatidylserine, plasmalogens, and cholestryl esters (Table 3,
Fig. 3, S3 Fig.). Taken together we had built two robust comparison groups for future reference
and for the assessment of the children with interstitial lung diseases.
Samples of such children were collected with the help of the biobank of the kinds lung regis-
ter (www.kids-lung-register.eu), diagnosed in an approach very similar to that described re-
cently [19,32]. Depending on the degree of diagnostic confidence reached and the diagnosis
obtained, the children were grouped into categories. These categories were based on the disease
classification for biopsied cases [13], and extended to accommodate all entities encountered, as
described previously [14]. Within a category, the children with the same diagnosis were sub-
categorized. A consistent, methodological sound and simultaneous analysis of the biochemical
samples allowed testing of the hypothesis if certain categories may have similar lipid composi-
tions and also comparisons to other studies in the future.
Our hypothesis that the different categories of diagnosis will also capture patient groups
with similar lung lavage lipid compositions was confirmed to large extent but not throughout.
Clearly the four categories diffuse developmental disorders, chronic tachypnoe of infancy, ILD
related to lung vessels and the heart, or ILD related to reactive lymphoid lesions were not asso-
ciated with any significant changes in their surfactant lipid profile. This was consistent with the
supposition that in these interstitial lung diseases the pulmonary surfactant system is
not involved.
The two categories ILD in the immune intact host and ILD in the immuno-compromised
host contained groups of diseases which proved to have different lipid pattern than others
from within the same category. With no changes in the surfactant typical phospholipid classes,
plasmalogen, phosphatidylserine, ceramide or cholesteryl esters were present, indicating a role
of admixing inflammatory lipoprotein components. In the substantial group of children in-
cluded here with hypersensitivity pneumonitis, we did not observe small alterations reported
in adult patients with this condition, i.e. about 2 fold increased sphingomyelin levels [33,34].
A major finding was the ascertainment that the children in disease categories having in
common a clear and significant morphological involvement of the alveoli must not all have
changes of the surfactant phospholipids. On the other hand, lipidomic analysis may give deep
diagnostic and functional insights, as exemplified in subjects with ABCA3 mutations.
Surfactant Lipidomics in Children
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ABCA3-deficiency from two disease causing mutations results in the derangement of type 2
cell surfactant lipid transport into lamellar bodies and subsequent secretion of surfactant into
the alveolar space [35,36]. Previously the surfactant phospholipid profile was determined using
2-dimensional thin-layer chromatography and phosphatidylcholine comprised 41% of the
total phospholipids in the BAL fluid of 8 patients with ABCA3 mutations [37]. Phosphatidyl-
glycerol was also reduced. This result is consistent to what we found in the patients investigated
here. In addition we detail the species changes, which give a clue to the specificity of the failing
transporting activity of ABCA3 (Fig. 6). Clearly the major surfactant phosphatidylcholine spe-
cies PC 30 and 32 and the phosphatidylglycerol species PG 32:1, PG 34:0, PG 36 to 38 irrespec-
tive of their degree of saturation, except PG 36:3, were severely depleted in surfactant of these
children. Our data confirm and extend results in ABCA3 -/- knockout mice, which showed re-
duced PC 30:0, 32:1, 32:0, 34:1, 38:6, as well as PG 32:1, 32:0, 34:1, 36:4, 38:6 [35]. In those ani-
mals phosphatidylethanolamine was reduced, whereas in newborn and adult mice with
conditional deletion of Abca3 phosphatidylethanolamine was increased [35]. In our patients
total phosphatidylethanolamine was not altered. Taken together our data demonstrate the lipid
species likely to be transported by ABCA3 in vivo.
Lipidomic analysis of BAL from patients with only a single mutation in ABCA3 detected
and without lung biopsy to investigate lamellar body morphology by electron microscopy, may
give a clue for the presence or absence of ABCA3 deficiency (S1 Table). Two (patients 391,
541) of the 5 patients who died having a single disease causing mutation, had a lipid pattern
similar to infants with two mutations, suggesting a non-detected mutation may have been
missed by the exon analysis done. On the other, hand patient 719 had a disease causing muta-
tion, a normal surfactant lipid profile and a healthy long term outcome. Thus it is likely that
the mutation may have increased the risk for respiratory distress as described [38], without fur-
ther impact on course. Similarly in patient 1300, who had a single R288K mutation detected, a
normal lipid profile and a favorable course make the causal involvement of this relatively fre-
quent but not clearly benign mutation less likely [39]. Lastly, patient 199 had a single disease
causing mutation identified and died of respiratory distress. However the lipid profile was nor-
mal, making ABCA3-related surfactant dysfunction an unlikely cause of death.
These conclusions may be broadened to children with histologically or clinically significant
derangement of the alveolar surfactant space. Of interest, in proven chronic pneumonitis of in-
fancy (CPI), desquamative interstitial pneumonitis and children with familial unclear RDS in
the mature neonate, and the diagnostic exclusion of mutations in SFTPB, SFTPC and ABCA3,
no major deviations from normal surfactant composition were observed, suggesting the pres-
ence of causes outside the surfactant system but resulting in severe alveolar tissue disintegra-
tion (Fig. 5, S5 Fig.). Conversely, a subject (507) with the histological diagnosis of NSIP (non-
specific interstitial pneumonitis) and in the absence of TTF1, SP-C or ABCA3 mutations had
considerably reduced level of phosphatidylcholine and such changes of their lipid species pro-
file suggesting the presence of as yet undetermined defects of the pulmonary surfactant system.
Such a defect was proven in a child with a mutation in the TTF1/NKX2–1 gene (659) [17].
Thus lipidomic profiles can yield useful diagnostic or pathophysiologic information in some
alveolar diseases. In others they may be of less diagnostic value, but nevertheless may substanti-
ate lack of significant involvement of mechanisms related to lipid metabolism. It is beyond the
scope of this manuscript to discuss all individual cases presented here; however when revisiting
such patients, recall of the lipidomic profile may be helpful.
Despite the overall large sample size, a weakness of the study was a relatively small case
number in several ultra-rare diseases. Thus all statistical results have to be interpreted with
great caution. In addition, to overcome this shortage we provide an open access repository of
the individual data of all subjects included (S1 Table). It is envisioned that similar and new
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cases of these rare entities will be merged internationally, to increase the pool of specific dis-
eases available for analysis. This will also make possible to investigate other confounding fac-
tors like age or diet [40].
Major strengths of this study are the presentation of the lavage lipidomic profile in two ro-
bust non-chILD control and comparison populations, together with inclusion of almost the en-
tire spectrum of children’s interstitial lung disease. In such a group, for the first time patho-
physiologically relevant disease markers sampled by standardized technique were comprehen-
sively analyzed in one batch. The species differentiation of the lipids recovered by bronchoal-
veolar lavage allows an improved differentiation of interfering endogenous and exogenous
factors over analysis using thin layer chromatography. Admixture of inflammatory cells as well
as of plasma can be identified because of their characteristic lipid composition. Granulocytes
are rich in plasmalogenes [41] and plasma leakage into the alveolar space may lead to increased
cholesteryl esters due to their high concentration in lipoproteins [42]. More importantly, infor-
mation on surfactant composition can be obtained with relatively little invasiveness from the
lungs and may directly proof involvement of genetically aberrant surfactant metabolic path-
ways. This study clearly indicated the complexity of BAL lipidomics which may be a useful re-
search tool. The results also define the stage for further selecting investigations in promising
subgroups of chILD, as exemplified by our results in patients with ABCA3 mutations. The po-
tential pathophysiological or metabolic role of specific lipid analytes may be proven in suitably
sized and homogenous patient groups. Such an ex vivo approach may then complement the re-
cently successfully used in vitro characterization of novel lipid pathways in cultured fibroblasts,
identified by next generation sequencing [43].
Conclusions
Lipidomic profiling identified specific forms of ILD in children with surfactant alterations and
characterized the molecular species pattern likely to be transported by the lipid transporter
ABCA3 in vivo.
Supporting Information
S1 Fig. A: Overview of the presentation arrangement of the lipid results as reported in the
manuscript and online supplemental material. B: Score plot of a principal component analy-
sis based on the lipid concentrations of 143 lipid subspecies for 115 patients. Groups 1 through
12 are defined in Table 1. Mainly patients from group 9 (ILD related to alveolar surfactant re-
gion) separate from the other patients. Percentage numbers in brackets denote the explained
variance of the respective principal component.
(PDF)
S2 Fig. Phospholipid classes of the control groups (healthy (n = 11), left column of pair;
bronchitis (n = 10), right column of pair). Lipid class composition is expressed as % of the
analysed displayed lipid classes. The species of the different lipid classes are alo displayed. Data
are means. Deviations from 100% are the result minor lipid species present at an abundance of
< 0.5%; these were included in the calcualtions, but were not displayed in the graphs. Phospha-
tidylcholine species annotation was based on the assumption of even numbered carbon chains
only. Other glycerophospholipid species were annotated based on the assumption that diacyl
species are present. SM species annotation is based on the assumption that a sphingoid base
with two hydroxyl groups is present.
(PDF)
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S3 Fig. Display of results at the disease category level. All lipid classes and their species com-
position are given as individual results of all patients included in the study according the dis-
ease category they belong to. Phosphatidylcholine species annotation was based on the
assumption of even numbered carbon chains only. Other glycerophospholipid species were an-
notated based on the assumption that diacyl species are present. SM species annotation is
based on the assumption that a sphingoid base with two hydroxyl groups is present. The statis-
tical comparisons were done by ANOVA and Dunn’s post hoc test; all significant results are
displayed in each figure. The significance of ANOVA was determined by comparison of the
raw P value given with the one calculated to take multiple comparisons into consideration,
(P<0.0182 instead of P<0.05). The significant results of Dunn’s post hoc tests are indicated as
following: ____ = P< 0.05, _ _ _ = P< 0.01, and . . .. = P< 0.001.
(PDF)
S4 Fig. Display of results at the individual diagnosis level for the disease category “ILD-
related to the alveolar surfactant region”. Phospholipid class composition and all species
compositions of all classes assessed are indicated as means for each diagnosis. The number of
subjects per group is detailed in Table 1. The numbers above the columns indicate the phos-
pholipid concentration analysed (μmol/l). No statistical comparisons were done. Deviations
from 100% are the result minor lipid species present at an abundance of< 0.5%; these were in-
cluded in the calculations, but were not displayed in the graphs.
(PDF)
S5 Fig. Display of results at the individual diagnosis level for the disease category “Unclear
RDS in the mature neonate”. Phospholipid class composition and all species compositions of
all classes assessed are indicated as means for each diagnosis. The number of subjects per
group is detailed in Table 1. The numbers above the columns indicate the phospholipid con-
centration analysed (μmol/l). No statistical comparisons were done. Deviations from 100% are
the result minor lipid species present at an abundance of< 0.5%; these were included in the




S1 Table. All individual values ordered by patients included in the final analysis, disease
category and subcategory. All lipid results are indicated. Note that in 7 of the patients PE P
and in 2 PG were not measured. Results are indicated in the units above the columns, for the
different lipid species, as percent of the lipid class. Phosphatidylcholine species annotation was
based on the assumption of even numbered carbon chains only. Other glycerophospholipid
species were annotated based on the assumption that diacyl species are present. SM species an-
notation is based on the assumption that a sphingoid base with two hydroxyl groups is present.
(PDF)
S2 Table. Phosphatidylcholine and phosphatidylglycerol and their species composition in
BAL from healthy children (n = 11) in comparison to children with two disease causing
ABCA3 mutations (n = 5). The individual values of the other phospholipid classes and their
species are depicted in the S1 Table.
(PDF)
S3 Table. Column statistics of the different patient groups depicted in the S3 Fig. indicat-
ing parameters in addition to means.
(PDF)
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